# Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia

> **NCT05576181** · PHASE1 · UNKNOWN · sponsor: **Fundamenta Therapeutics, Ltd.** · enrollment: 19 (estimated)

## Conditions studied

- Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited

## Interventions

- **DRUG:** ThisCART19A
- **DRUG:** Fludarabine Oral Tablet
- **DRUG:** Cyclophosphamide
- **DRUG:** VP-16
- **PROCEDURE:** HSCT

## Key facts

- **NCT ID:** NCT05576181
- **Lead sponsor:** Fundamenta Therapeutics, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-15
- **Primary completion:** 2025-01-22
- **Final completion:** 2025-07-22
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2022-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576181, "Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05576181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*